预约演示
更新于：2025-07-03
Levothyroxine Sodium
左甲状腺素钠
更新于：2025-07-03
概要
基本信息
简介左旋甲状腺素钠是一种小分子药物，作用于甲状腺激素受体，是甲状腺激素受体的激动剂。左旋甲状腺素钠可以调节人体新陈代谢，用于治疗垂体前叶功能亢进、甲状腺功能亢进、甲状腺肿、甲状腺功能减退等多种疾病。其作用机制是增加甲状腺激素的水平，从而调节人体的新陈代谢、心血管系统、中枢神经系统等方面的功能。左旋甲状腺素钠是由AbbVie公司开发的，并于1964年8月7日首次获得批准。 |
药物类型 小分子化药 |
别名 Levothyroxine Sodium Hydrate、LT4、Sustained-release levothyroxine sodium + [31] |
靶点 |
作用方式 激动剂 |
作用机制 THR激动剂(甲状腺激素受体激动剂) |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1964-08-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H13I4NNaO5 |
InChIKeyVSGRWOHSMUGJIF-LTCKWSDVSA-N |
CAS号6106-07-6 |
关联
290
项与 左甲状腺素钠 相关的临床试验NCT06790589
COmparison of Two Alternative Thyrotropin Suppression Strategies Among Patients With Advanced Differentiated Cancer of the tHyroid
NCT07011953
A Clinical Trial of Adjunctive Thyroxine for Avolition in Schizophrenia
NCT06971965
Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.
100 项与 左甲状腺素钠 相关的临床结果
登录后查看更多信息
100 项与 左甲状腺素钠 相关的转化医学
登录后查看更多信息
100 项与 左甲状腺素钠 相关的专利（医药）
登录后查看更多信息
62,006
项与 左甲状腺素钠 相关的文献（医药）2025-10-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Warburg effect in malign thyroid tissue evidenced using FTIR spectroscopy
Article
作者: Garcia-Hernandez, Juan Salvador ; Tamaniz-Marcos, Izanami ; Mata-Miranda, Monica Maribel ; Becerril-Galeana, Christian Andrei ; Martinez-Cuazitl, Adriana ; Vazquez-Zapien, Gustavo Jesus ; Garibay-Gonzalez, Francisco ; Hernandez-Abarca, Edgar ; Delgado-Gonzalez, Luis Eduardo
BACKGROUND/OBJECTIVES:
Thyroid cancer is the most common endocrine malignancy; the clinical approach of nodular thyroid involves ultrasonography (USG) TI-RADS classification, clinical symptoms, and biopsies according to the Bethesda System, highlighting that biomarkers also support diagnosis. The main objective of this research is to compare the chemometric changes by Fourier transform infrared (FTIR) spectroscopy analysis between benign tumor (BT) vs. malignant neoplasm (MN) and thyroid pathology (TP) vs. healthy tissue (HT).
METHODS:
Biopsies of thyroid nodular disease were obtained and analyzed by ATR-FTIR spectroscopy; thereafter, BT and MN biomolecular compounds were compared, as well as TP vs HT. Prior biopsies, laboratory blood tests, USG TI-RADS classification, and thyroid cytopathology report (BETHESDA classifier) were obtained.
RESULTS:
Laboratory blood tests showed that glucose and urea levels were similar in BT and MN, but in MN, the creatinine increased, and the albumin decreased compared to BT, with no differences in thyroid hormones. About the TI-RADS scoring system in the MN group, 52 % were unknown, followed by 4 (30 %). However, no significant differences in the size of the tumors were shown. The most reported Bethesda for BT was I, followed by IV and V. Contrary for the MN was VI, followed by V. The FTIR analysis showed shifts in all the analyzed biomolecules, highlighting the evidence of the Warburg effect on MN. Moreover, an increase in protein vs. lipid and protein vs. DNA (1650/1453 and 1550/1082 ratios) was observed, as well as decreased levels of DNA content about proteins and lipids (1550/1082 and 1082/1453 ratios). Besides, structural changes related to lipids (2962 cm-1, 2877 cm-1), fatty acids (1401 cm-1), amide III (1317 cm-1), and nucleic acid (1239 cm-1) were found on TP in comparison to HT. In this sense, TP showed decreased levels in proteins vs DNA and increased levels of DNA compared to lipids CH2.
CONCLUSIONS:
Metabolic alteration in MN was evidenced, reflecting the "Warburg effect," with a significant decrease in lipids and DNA compared to protein content. In the same way, structural changes related to lipids, fatty acids, amide III, and nucleic acids were found in TP compared to HT. However, more studies are needed.
2025-10-01TISSUE & CELL
Construction of a 3D trophoblast model and validation by triiodothyronine (T3) treatment
Article
作者: Tilli, Helena P ; Sakalem, Marna E ; Olímpio, Regiane M C ; Vieira, Ester M ; Padovani, Carlos R ; Peghinelli, Vinícius V ; Gonçalves, Bianca M ; Rocha, Paula B ; de Sibio, Maria T ; Nogueira, Célia R ; Mathias, Lucas S ; Deprá, Igor C ; Lourenço, Mariana M
During gestation, insufficient triiodothyronine hormone (T3) can lead to failures in trophoblastic activity or induce defects in fetal epigenetic mechanisms. As a consequence, multiple hormones become unbalanced, which can trigger different negative outcomes in the offspring. This study aims to propose the construction of a 3D trophoblast model, validated with different levels of thyroid hormone treatment. Different concentrations of T3, 1, 10 and 100 nM, were employed for 24, 48 and 72 h, corresponding to sub-physiological, physiological and supraphysiological concentrations, respectively, to investigate the effects on human chorionic gonadotropin (hCG), Lactate Dehydrogenase (LDH), and MTT levels in the 3D model. The generated 3D trophoblast model responded differently to the T3 concentrations: although no effect was observed regarding cell viability (MTT assay), there was an increase in cytotoxicity in the group treated with the highest concentration (100 nM; LDH assay) after 24 h. In addition, in the concentration-response curve of hCG, while a natural progressive increase in hCG is observed in control group, there was a clear reduction of hCG in the models treated with 1 nM and 100 nM T3; the 10 nM-treated group demonstrated no difference to control. The proposed 3D trophoblastic placental model was successfully established and validated. Utilizing this model, it was demonstrated that adequate concentrations of T3 are essential for the accurate prediction of cellular function and the prevention of cytotoxic effects. These findings underscore the critical importance of maintaining physiological levels of T3 during pregnancy to support appropriate secretion of hCG.
2025-09-01LIFE SCIENCES
Thyroid hormone ameliorates ursodeoxycholic acid-induced heart damage in zebrafish embryos
Article
作者: Hu, Jian ; Zhang, Chunxiang ; Li, Chunhong ; Zhou, Xiangyu ; Wu, Haoran ; Wang, Xueqin ; Zhu, Jinshun ; Li, Honghao
Ursodeoxycholic acid (UDCA) is the most commonly prescribed treatment for intrahepatic cholestasis of pregnancy (ICP) worldwide. Clinical studies show that UDCA helps alleviate maternal pruritus and lowers serum bile acid levels. However, despite treatment, women with ICP still experience unpredictable fetal deaths and other serious pregnancy complications. In this study, we hypothesize that while UDCA improves maternal symptoms, it may have harmful effects on the fetus due to its placental barrier crossing, potentially leading to negative pregnancy outcomes. We found that UDCA concentrations above 150 mg/L can exert toxic effects on zebrafish embryos, including increased mortality, slower heart rates, and pericardial edema. At these concentrations, UDCA also triggered apoptosis and elevated oxidative stress in embryonic cardiomyocytes. Importantly, the thyroid hormone T4 was able to partially mitigate these toxic effects. These findings suggest that adverse pregnancy outcomes in ICP may be related to fetal heart damage caused by UDCA's effects on circulation, providing a possible explanation for fetal death in clinical settings. This also underscores the need to optimize UDCA dosing in clinical practice and explore the use of thyroid hormones as a potential protective therapy for the fetus in ICP cases.
100 项与 左甲状腺素钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 分化型甲状腺癌 | 美国 | 2022-04-29 | |
| 粘液性水肿昏迷 | 美国 | 2011-06-24 | |
| 垂体功能亢进 | 美国 | 2001-05-25 | |
| 甲状腺功能亢进症 | 中国 | 2000-01-01 | |
| 甲状腺癌 | 中国 | 2000-01-01 | |
| 甲状腺肿 | 日本 | 1998-02-12 | |
| 先天性甲状腺功能减退症 | 韩国 | 1974-04-06 | |
| 粘液水肿 | 韩国 | 1974-04-06 | |
| 甲状腺功能减退症 | 日本 | 1964-08-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | iodine metabolism status assessed by urinary iodine excretion | 150 | Prophylactic LT4 treatment | 艱簾襯憲衊衊鹹膚鹽鑰(糧襯製觸膚壓鹹襯艱艱) = 積鏇淵製築餘膚範窪選 顧壓簾網製遞齋襯築顧 (鏇範艱廠壓蓋繭願構範 ) | 积极 | 2025-01-01 | |
No LT4 treatment | 艱簾襯憲衊衊鹹膚鹽鑰(糧襯製觸膚壓鹹襯艱艱) = 鏇構襯構構築窪膚築選 顧壓簾網製遞齋襯築顧 (鏇範艱廠壓蓋繭願構範 ) | ||||||
N/A | 105 | (Transient CH) | 獵積顧繭築衊鹹積構觸(遞範壓鑰鹽艱衊鏇積繭) = 窪構願觸淵壓鏇鑰壓遞 襯積衊鑰襯選顧範構鬱 (鏇廠願淵醖糧餘醖夢網 ) | - | 2024-06-01 | ||
(Permanent CH) | 獵積顧繭築衊鹹積構觸(遞範壓鑰鹽艱衊鏇積繭) = 餘願鹽襯構範廠齋鹹願 襯積衊鑰襯選顧範構鬱 (鏇廠願淵醖糧餘醖夢網 ) | ||||||
N/A | - | 製齋鬱遞夢齋壓願壓壓(製餘鹽廠淵製醖蓋餘窪) = Rhabdomyolysis due to hypothyroidism, without an obvious precipitating factor, has been previously reported, but is very rare 獵顧築艱憲鹽憲積獵窪 (積鬱築顧淵夢壓繭製鏇 ) | - | 2024-06-01 | |||
N/A | - | - | 淵鹽鏇衊選獵網獵製鹹(遞製顧淵憲壓糧餘願觸) = present 觸繭簾襯顧夢願獵鹽鏇 (廠鏇衊夢壓觸觸壓獵網 ) 更多 | - | 2024-06-01 | ||
IV Synthroid 500 mcg weekly infusions | |||||||
N/A | 45 | LT4/LT3 combination therapy | 憲憲蓋蓋齋範簾鹽壓醖(蓋齋製顧遞網構選廠膚) = 齋獵襯蓋鏇積網蓋範鬱 範艱繭鑰鹹蓋鹽簾淵鑰 (蓋齋淵範糧構衊憲觸憲 ) 更多 | 积极 | 2024-06-01 | ||
憲憲蓋蓋齋範簾鹽壓醖(蓋齋製顧遞網構選廠膚) = 鏇膚簾衊醖繭築艱淵廠 範艱繭鑰鹹蓋鹽簾淵鑰 (蓋齋淵範糧構衊憲觸憲 ) 更多 | |||||||
N/A | - | 繭鹽繭鑰網鬱衊艱憲鹹(積齋構齋鬱觸繭齋鹹淵) = 餘鹹壓網艱齋製窪鹹簾 蓋鹽衊選範廠鏇遞鑰憲 (鑰鑰顧遞網鏇網願積選 ) 更多 | - | 2024-06-01 | |||
繭鹽繭鑰網鬱衊艱憲鹹(積齋構齋鬱觸繭齋鹹淵) = 顧膚構鬱淵壓製選選襯 蓋鹽衊選範廠鏇遞鑰憲 (鑰鑰顧遞網鏇網願積選 ) 更多 | |||||||
临床2期 | 46 | 積憲壓鏇窪積艱製範齋(憲夢鏇艱鑰觸夢廠壓膚) = 膚簾膚簾鏇鏇鏇膚蓋獵 衊糧餘範淵鏇範構鏇繭 (糧艱廠壓膚夢網廠簾糧 ) | 积极 | 2024-05-30 | |||
临床3期 | 838 | (Thyroxine) | 廠築鹽構顧鹹鹹積範窪 = 齋衊繭構選鬱網鏇廠構 簾獵醖壓網膚衊鑰繭獵 (膚襯繭積觸鏇夢憲鏇鬱, 淵蓋願觸簾襯製膚衊艱 ~ 築鹹網鬱製窪鏇醖願繭) 更多 | - | 2024-01-10 | ||
(Saline Placebo) | 廠築鹽構顧鹹鹹積範窪 = 構淵齋獵製積製淵繭積 簾獵醖壓網膚衊鑰繭獵 (膚襯繭積觸鏇夢憲鏇鬱, 製願壓觸廠築繭獵憲鹹 ~ 襯窪遞蓋糧遞窪獵積蓋) 更多 | ||||||
临床4期 | serum thyrotropin (TSH) | free thyroxine (fT4) | total thyroxine (TT4) ... 更多 | - | Levothyroxine Sodium Soft Gelatin Capsules (Tirosint) | 鑰築襯積膚醖鹽淵糧築(餘窪鹽衊獵鬱窪糧獵鑰) = 積窪願衊糧糧範鹹築醖 選壓壓製繭鹽糧觸鏇壓 (網夢網糧鏇遞膚襯衊築 ) 更多 | 积极 | 2023-12-01 | |
N/A | - | T4/T3 (Armour) 60mg daily | 糧鹹壓鑰鏇膚餘鏇鏇糧(獵醖獵膚蓋齋製鏇壓壓) = 夢鑰襯遞顧顧膚醖鑰膚 淵襯網願範獵衊積構網 (積糧製齋鹹淵醖齋築選 ) 更多 | - | 2023-10-05 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用